Research programme: antibacterial therapeutics - BioVersys
Alternative Names: BV-500Latest Information Update: 24 Jun 2024
At a glance
- Originator BioVersys
- Class Antibacterials; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Nontuberculous mycobacterium infections
Most Recent Events
- 10 Jun 2024 Early research in Nontuberculous mycobacterium infections in Switzerland (Inhalation)
- 03 Oct 2023 BV 500 is available for licensing as of 03 Oct 2023. https://www.bioversys.com/partners/ (BioVersys website, October 2023)
- 03 Oct 2023 Early research in Nontuberculous mycobacterium infections in Switzerland (unspecified route) (BioVersys pipeline, October 2023)